Navigation Links
Generics Analysis: Key Patent Case Reviews
Date:9/20/2012

NEW YORK, Sept. 20, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Generics Analysis: Key Patent Case Reviews

http://www.reportlinker.com/p0968573/Generics-Analysis-Key-Patent-Case-Reviews.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Providing clarity regarding generic launch timing that will shape the market around Eli Lilly's antidepressant Cymbalta and Celgene's oncology drug Revlimid.Detailed analysis of the likely date of generic entry for Cymbalta and RevlimidAnalysis of both products' position in their companies total prescription pharma portfolioCelgene is heavily dependent upon the performance of Revlimid (lenalidomide). The product generated $3.2bn in 2011, or 68.3% of the company's total sales.The only generic version submitted so far in the US is from Natco and partner Watson. A 30-month stay runs until December 2013 and the companies have been sued for infringement of 14 patents covering Revlimid, which expire across 2016–27.In 2012 and 2013, Cymbalta is forecast to account for 17.5% of Eli Lilly's total five major EU market sales. As such, generic launch timing will have a significant impact.Gain clarity on when Cymbalta and Revlimid are likely to face generic competitionAssess the threat to Eli Lilly and Celgene of these products' genericization

 

GENERIC ENTRY TIMING REVIEWS•Key findings

•Cymbalta (duloxetine; Eli Lilly) - EU launch of generic Cymbalta from August 2014

•Revlimid (lenalidomide; Celgene) - Natco sued for infringement of 14 patents

 

APPENDIX•References

•Exchange rates

 

TABLES

•Table: Cymbalta: patent protection and exclusivity in Europe

•Table: Revlimid: patent protection and exclusivity in the US

•Table: Exchange rates, 2012

 

FIGURES

•Figure: Cymbalta/Xeristar and Eli Lilly total five major EU market sales, 2002–17

•Figure: Revlimid and total Celgene sales, 2002–17

•Figure: US patent and exclusivity timeline relating to Revlimid

•Figure: Chemical structure of lenalidomide

 

Companies Mentioned

Devoteam SA, Hutchison 3G UK Limited

 

To order this report:

Drug_and_Medication Industry: Generics Analysis: Key Patent Case Reviews

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Prodigy Generics and eVenus Announce the Launch of Oncology Injectable Irinotecan.
2. Generics in the Antivirals Market to 2018 - Launch of Generic Combivir and Patent Expiry of Sustiva, Kaletra and Epivir-HBV will Drive Volume Growth
3. Pfizer and Mylan Team Up to Establish Exclusive Long-Term Strategic Collaboration to Drive Sustained Growth of Generics Business in Japan
4. Branded Generics in South East Asia: Current and Future Opportunities
5. Essential Medical Dismisses Patent Case against Masimo and Cercacor
6. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
7. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
8. U.S. Patent Office Issues Sixth Patent Covering Zero-Footprint Medical Image Viewers to Heart Imaging Technologies, LLC
9. Biodels Intellectual Property Position Strengthened for Ultra-Rapid-Acting Insulin Programs by Notice of Intent to Grant from European Patent Office
10. DURECT Announces Issuance of U.S. Patents Covering ORADUR® Technology
11. Broad Patent Protection Granted for iBio Immunomodulator
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Dublin - ... " Global Markets for Spectroscopy Equipment" report ... This report focuses on the global market of ... applications in various applications. The report deals with spectroscopy ... industries: pharmaceutical and biotechnology, food and beverage, and environmental ...
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016  American Respiratory ... testing company, is now able to perform sophisticated lung assessments in ... Medical Technologies , Inc. Patients are no longer ... to ndd,s EasyOne PRO ® , ARL patients like Jeanne R. ... testing done in the comfort of her own home. ...
Breaking Medicine Technology:
(Date:6/26/2016)... Charlotte, NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind ... able to be personalized through a fitness app. The fitness app plans to fix the ... solutions currently only offer a one size fits all type program , They ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from PsychTests.com reveals that behind the tendency to set low expectations ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing skills ... patients and their families pay tribute to a genetic counselor by nominating him or ... Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome magazine ...
Breaking Medicine News(10 mins):